SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
These results suggest for the first time that endogenous cannabinoid systems may modulate the appetitive value of sucrose and ethanol, perhaps by affecting the activity of brain reward systems.
SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
- C. Cohen, G. Perrault, C. Voltz, R. Steinberg, P. Soubrié
- Biology, ChemistryBehavioural Pharmacology
- 1 September 2002
Results suggest that activation of the endogenous cannabinoid system may participate in the motivational and dopamine-releasing effects of nicotine and ethanol, and may be effective in reduction of alcohol consumption, as previously suggested, and as an aid for smoking cessation.
Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats
Findings indicate that, on their own, CB receptor agonists are unable to generate the processes necessary to induce a pleasurable state in animals, as assessed in place conditioning procedures.
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Results show that SR141716 stimulated Acrp30 mRNA expression in adipose tissue by an effect on adipocytes, and reduced hyperinsulinemia in obese (fa/fa) rats, and suggest a role of metabolic regulation in the antiobesity effect of SR 141716.
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.
- C. Ravinet Trillou, M. Arnone, P. Soubrié
- Biology, MedicineAmerican Journal of Physiology. Regulatory…
- 1 February 2003
It is suggested that SR141716 has a potential as a novel anti-obesity treatment and may influence metabolic processes as the body weight loss of SR 141716-treated mice was significantly higher during 24-h fasting compared with vehicle-treated animals, and when a 3-day treatment was compared with a pair feeding.
The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance
The data clearly indicated that SR141716 reversed the phenotype of obese adipocytes at both macroscopic and genomic levels, and strongly indicate that the endocannabinoid system has a major role in the regulation of energy metabolism.
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
- G. Griebel, J. Simiand, P. Soubrié
- Psychology, BiologyProceedings of the National Academy of Sciences…
- 16 April 2002
Findings point to a role for vasopressin in the modulation of emotional processes via the V1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
- C. Trillou, C. Delgorge, C. Menet, M. Arnone, P. Soubrié
- Biology, MedicineInternational Journal of Obesity
- 1 April 2004
Evidence is provided that the stimulation of CB1 receptors is a key component in the development of diet-induced obesity, and that these receptors and their endogenous ligands are implicated not only in feeding control but also in peripheral metabolic regulations.
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a…
- C. Serradeil-Le Gal, J. Wagnon, G. Le Fur
- Biology, ChemistryJournal of Pharmacology and Experimental…
- 1 March 2002
SSR149415 is a potent, selective, and orally active V1b receptor antagonist and deserves to be clinically investigated in the field of stress and anxiety.